Stephen F. Flaim, Ph.D.

Dr. Flaim holds a doctorate in Human Physiology and Pharmacology from the University of California at Davis. He held faculty positions in Medicine and Physiology at the Pennsylvania State University College of Medicine and senior management roles at the Johnson & Johnson Pharmaceutical Research Institute, the Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation, Trega Biosciences, Inc. and Galileo Pharmaceuticals, Inc. Dr. Flaim is Founder and President of Flaim Partners Consulting, a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a board member of Pivotal Biosciences, Inc., on the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics, a Technology and Business advisor to the William J. von Liebig Center for Entrepreneurism and Technology Advancement at the University of California, San Diego, a member of the Board of Directors and Vice Chair of the Tech Coast Angels, President of the San Diego Tech Coast Angels, an Entrepreneur-in-Residence with CONNECT, and is also active in numerous regional and national scientific organizations. Dr. Flaim is Cofounder and CEO of CardioCreate, Inc. and Chairman & CEO of OncoFluor, Inc.

Employer:	Tech Coast Angels
Position:	Vice Chairman Elect
Time period:	January 2011 - Present

Employer:	OncoFluor, Inc.
Position:	Chairman, President & CEO
Time period:	January 2008 - Present
Description:	Product Areas: Injectables for direct visualization of tumor margin and metastatic tissue, tumo diagnostic kits and imaging tools Chairman, Board of Directors

Employer:	CardioCreate, Inc.
Position:	Founder, President & CEO
Time period:	January 2008 - Present
Description:	Product Areas: Modified adult cardiac stem cell therapy for myocardial ischemia and congestive heart failure Member, Board of Directors

Employer:	Flaim Partners Consulting
Position:	President
Time period:	January 2004 - Present
Description:	Drug discovery Diagnostics Preclinical and clinical product development Strategic planning Project management Operational planning and execution Recruiting Entrepreneurism & business development

Employer:	Tech Coast Angels
Position:	Vice President
Time period:	January 2008 - December 2010
Description:	Member, Board of Directors Member, BioMed Track Pre-Screen Committee Due diligence, valuation, intellectual property, risk assessment Term sheet negotiation

Employer:	Galileo Laboratories, Inc.
Position:	Senior Vice President, Research & Development
Time period:	January 2001 - December 2004
Description:	Product Areas: Myocardial ischemia, stroke, anti-inflammatory, chronic neurological diseases Member, Executive Committee for corporate management and strategic planning Directed company build-out from 75 to 150 people over 2-year period Responsible for Medicinal, Physical, Analytical & Natural Products Chemistry, Cell & Molecular Biology, Bioanalytical & Drug Disposition, Drug Safety, Pharmacology, Animal Resources, and Clinical Development & Regulatory Affairs Directed development of IPO process and hiring of appropriate personnel Directed preclinical and clinical development of nutriceutical product lines addressing consumer and medical product requirements Directed discovery and development to IND application of pharmaceutical products

Employer:	Galileo Laboratories, Inc.
Position:	Vice President, Research & Development
Time period:	January 1999 - December 2001
Description:	Member, Executive Committee for corporate management and strategic planning Directed R&D build-out from 18 to 150 people over 3-year period Directed Medicinal & Analytical Chemistry, Cell & Molecular Biology, Pharmacology, Animal Resources, and Clinical Development Directed identification and responsible for preclinical and clinical development of nutriceutical product lines addressing consumer and medical product requirements Directed discovery and development of pharmaceutical products for myocardial ischemia and stroke

Employer:	Trega Biosciences, Inc.
Position:	Vice President, Biological Research & Development Officer of the Corporation
Time period:	January 1998 - December 1999
Description:	Product Areas: Diabetes, obesity, metabolic disease, anti-inflammatory, pain Member, Executive Committee for corporate management and strategic planning Successful recruitment of new CEO and acquisition of NaviCyte Contributed to success of early Phase II clinical trials on HP228 (analgesic) Steering Committee member for two major international R&D partnerships Built consensus for & successfully accomplished reorganization of the Division of Biological Research & Development Built Department of Pharmacokinetics, Drug Metabolism & Bioanalytical Sciences including a Director and 3 Ph.D. Sections Heads Supervised Division of four departments (Cell & Molecular Biology, Pharmacology, Animal Sciences, Pharmacokinetics & Drug Metabolism) containing approximately 40 individuals including 10 PhDs Resigned due to corporate restructuring

Employer:	Alliance Pharmaceutical Corp.
Position:	1996.1998Vice President, Biological Sciences Officer of the Corporation
Time period:	January 1996 - December 1998
Description:	Product Areas: Ultrasound contrast agents, adult respiratory distress syndrome, high blood-loss surgery, surgical adhesions, anti-inflammatory Grew biology program from 35- to 50-member organization including 19 PhDs Directed six departments (Biochemistry, Cell & Molecular Biology, Experimental Biology, Biology Technical Affairs, Biology Research Services, Bioengineering, and Drug Safety) which successfully supported 4 products into late-phase clinical trials Overall responsibility for successful planning, development, execution and reporting all safety and efficacy programs for 5 products and devices in development Shared responsibility for corporate new-product acquisition activities Resigned to assume position of Vice President of Biological Research & Development at Trega Biosciences, Inc.

Employer:	Biological Sciences
Position:	Division Director
Time period:	January 1992 - December 1996
Description:	Grew the biology program from 10- to 35-member organization including 8 PhDs Established Department of Biochemistry, Cell & Molecular Biology with director & staff Led site identification, design, construction, outfitting, and staffing of 30,000 sq. ft biology research facility including 17,000 sq. ft AAALAC-accredited vivarium Made numerous scientific, regulatory, and partnering diligence presentations resulting in successful partnering and regulatory filing of Oxygent HT, Imagent US, and LiquiVent

Employer:	Pharmacology & Toxicology
Position:	Division Director
Time period:	January 1990 - December 1992
Description:	Grew the biology program from 3- to 10-member organization including 4 PhDs Established Departments of Toxicology, Pharmacology, & Biology Technical Affairs & successfully recruited Directors and staff Established comprehensive biology data reporting, filing, and retrieval procedures Organized, prepared and provided regulatory representation of preclinical files for Imagent BP IND and for Imagent GI NDA

Employer:	Bristol-Myers Squibb
Position:	Associate Director, Pharmacology
Time period:	January 1989 - December 1990
Description:	Product Areas: Ion channel regulation, antihypertensives, antiischemics, congestive heart failure Directed 5 labs containing 15 associates including 6 PhDs Launched endothelin antagonist & K-channel regulator drug discovery programs Established single-cell patch-clamp & intracellular fluorescence laboratories Resigned to assume position of Division Director, Pharmacology & Toxicology at Alliance Pharmaceutical Corp.

Employer:	Ion Channel Regulation, Pharmacology
Position:	Section Head
Time period:	January 1987 - December 1989
Description:	Responsible for pharmacology of myocardial ischemia, anti-arrhythmia and antihypertensive therapeutic areas; clinical candidates identified Directed Ca blocker drug discovery program; lead candidate selected Established Ca flux laboratory; became key component of drug discovery program Matrix management member of ACE-Inhibitor and ANF Drug Discovery Programs

Employer:	McNeil Pharmaceutical
Position:	Research Fellow, Biological Research
Time period:	January 1986 - December 1987
Description:	Product Areas: Antihypertensives, antianginals, congestive heart failure Directed 2 labs containing 6 associates including 2 MS scientists Identified 3 antianginal compounds as candidates for clinical trials

Employer:	Biological Research
Position:	Principal Scientist
Time period:	January 1982 - December 1986
Description:	Established Antianginal Drug Discovery Program; clinical candidate identified Biological Research representative on the Vascor development team; product approved for human use Presented Vascor preclinical summary to FDA Cardiorenal Advisory Committee Established vascular smooth muscle research laboratory & radioactive microsphere regional blood flow research laboratories

University:	University of California System - Davis
Time period:	1975
Degree:	Human Physiology, PhD

University:	Santa Clara University
Time period:	1970
Degree:	Biology, BSc

Articles:

1. Zelis, R., FLAIM, S.F., and Eisele, J.H.: The effects of morphine on the reflex arteriolar constriction induced in man by hypercapnia. Clinical Pharmacology and Therapeutics 22: 172-178, 1977. 2. FLAIM, S.F. and Zelis, R.: Effects of isoproterenol on adrenergic constriction in vascular smooth muscle. American Journal of Physiology 233: 22-26, 1977. 3. FLAIM, S.F., Vismara, L.A., and Zelis, R.: The effects of morphine on isolated cutaneous canine vascular smooth muscle. Research Communications in Chemical Pathology and Pharmacology 16: 191-194, 1977. 4. FLAIM, S.F., Zelis, R., and Eisele, J.H.: Differential effects of morphine on forearm blood flow: Attenuation of systemic control of the cutaneous circulation. Clinical Pharmacology and Therapeutics 23: 542-546, 1978. 5. FLAIM, S.F., Morris, Z.Q., and Kennedy, T.J.: Dextran as a radioactive microsphere suspending agent: Severe hypotensive effect in rat. American Journal of Physiology 235: H587-H591, 1978. 6. FLAIM, S.F. and Hsieh, A.C.L.: Effect of cold acclimation on rabbit carotid artery: Altered response to norepinephrine. General Pharmacology 9: 437-422, 1978. 7. FLAIM, S.F., Minteer, W.J., Clark, D.P., and Zelis, R.: Cardiovascular response to acute aquatic and treadmill exercise in the untrained rat. Journal of Applied Physiology: Respiratory, Environmental, and Exercise Physiology 46: 302-308, 1979. 8. FLAIM, S.F. and DiPette, D.J.: Digoxin-norepinephrine response and calcium blocker effects in vascular smooth muscle. American Journal of Physiology 236: H613-H619, 1979. 9. FLAIM, S.F., Crede, W., Beech, A., Nellis, S.H., and Zelis, R.: The effects of norepinephrine on active hyperemia in the canine gracilis muscle. Circulation Research 44: 660-666, 1979. 10. FLAIM, S.F., Minteer, W.J., Nellis, S.H., and Clark, D.P.: Chronic arteriovenous shunt: Evaluation of a model for heart failure in rat. American Journal of Physiology 236: H698-H704, 1979.

Books:

1. FLAIM, S.F. and Hsieh, A.C.L.: Evidence for increased beta-adrenergic receptor function in isolated perfused carotid artery from cold acclimated rabbits. In: Microcirculation. 1. Blood Vessel Interactions, Systems in Special Tissues. J. Grayson and W. Zingg, editors. New York: Plenum Press, 1976. pp. 264-265. 2. Zelis, R., FLAIM, S.F., Nellis, S.H., Longhurst, J., and Moskowitz, R.: Autonomic adjustments to congestive heart failure and their consequences. In: Heart Failure. A.P. Fishman, editor. New York: McGraw-Hill, 1978. pp. 237-247. 3. Zelis, R., Liedtke, A.J., and FLAIM, S.F.: Antianginal Drugs. In: Clinical Applications of Cardiovascular Drugs. Boston: Martinus Nijhoff, 1979. pp. 95-135. 4. FLAIM, S.F. and Zelis, R.: The effects of nitroglycerin on regional blood flow during exercise in heart failure. In: Vasodilatation. P.M. Vanhoutte and I. Leusen, editors. New York: Raven, 1981. pp. 469-475. 5. Zelis, R. and FLAIM, S.F.: Hemodynamic effects of vasodilator drugs. In: Vasodilatation. P.M. Vanhoutte and I. Leusen, editors. New York: Raven, 1981. pp. 441-449. 6. Zelis, R., Moskowitz, R.M., FLAIM, S.F., Piccini, P.A., Nellis, S.H., and Dash, H.: The effects of vasodilators on the circulation to skeletal muscle during exercise in congestive heart failure. In: Les Alpha-Bloquants, Pharmacologie Experimentale et Clinique. D. Bauman, editor. Paris: Masson, 1981. pp. 232-240. 7. FLAIM, S.F. and Zelis, R. editors. Calcium Blockers: Mechanisms of Action and Clinical Applications. Baltimore: Urban and Schwarzenberg, 1982. pp. 1-303. 8. FLAIM, S.F.: Comparative pharmacology of calcium blockers based on studies of vascular smooth muscle. In: Calcium Blockers: Mechanisms of Action and Clinical Applications. S.F. FLAIM and R. Zelis, editors. Baltimore: Urban and Schwarzenberg, 1982. pp. 155-179. 9. FLAIM, S.F. and Kanda, K.: Comparative pharmacology of calcium blockers based on studies of cardiac output distribution. In: Calcium Blockers: Mechanism of Action and Clinical Applications. S.F. FLAIM and R. Zelis, editors. Baltimore: Urban and Schwarzenberg, 1982. pp. 179-193. 10. Ratz, P.H. and FLAIM, S.F.: Species and blood vessel specificity in the use of calcium for contraction. In: Calcium Blockers: Mechanisms of Action and Clinical Applications. S.F. FLAIM and R. Zelis, editors. Baltimore: Urban and Schwarzenberg, 1982. pp. 77-99.

Memberships:

2011-present AnaBios Corporation, San Diego, CA 2010-present CONNECT, San Diego, CA 2008-present CardioCreate, Inc. 2008-present OncoFluor, Inc., San Diego, CA 2007-2008 Triton Innovation Network, San Diego, CA 2007-present Pivotal Biosciences, Inc., Los Angeles, CA 2006-present Tech Coast Angels Board of Directors, CA 2006-present San Diego Tech Coast Angels, San Diego, CA

Awards:

1999 American Heart Association Greater San Diego Division, Advocate Of The Year Award 1980-1982 National Institutes of Health, Young Investigator Award 1980 National Research Council, International Travel Award 1977-1978 National Institutes of Health, Research Service Award 1977 American Heart Association, British American Research Fellowship Award 1976 National Institutes of Health, Research Service Award 1975-1976 American Heart Association, Research Fellowship Award